|
1
|
Jie H, Ma W and Huang C: Diagnosis,
prognosis, and treatment of Triple-negative breast cancer: A
review. Breast Cancer (Dove Med Press). 17:265–274. 2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ensenyat-Mendez M, Llinàs-Arias P, Orozco
JIJ, Íñiguez-Muñoz S, Salomon MP, Sesé B, DiNome ML and Marzese DM:
Current Triple-negative breast cancer subtypes: Dissecting the most
aggressive form of breast cancer. Front Oncol.
11(681476)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Derakhshan F and Reis-Filho JS:
Pathogenesis of Triple-negative breast cancer. Annu Rev Pathol.
17:181–204. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bianchini G, De Angelis C, Licata L and
Gianni L: Treatment landscape of triple-negative breast
cancer-expanded options, evolving needs. Nat Rev Clin Oncol.
19:91–113. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Riaz F, Gruber JJ and Telli ML: New
treatment approaches for Triple-negative breast cancer. Am Soc Clin
Oncol Educ Book. 45(e481154)2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
De Francesco EM, Cirillo F, Vella V,
Belfiore A, Maggiolini M and Lappano R: Triple-negative breast
cancer drug resistance, durable efficacy, and cure: How advanced
biological insights and emerging drug modalities could transform
progress. Expert Opin Ther Targets. 26:513–535. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sethy C and Kundu CN: 5-Fluorouracil
(5-FU) resistance and the new strategy to enhance the sensitivity
against cancer: Implication of DNA repair inhibition. Biomed
Pharmacother. 137(111285)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bisht A, Avinash D, Sahu KK, Patel P, Das
Gupta G and Kurmi BD: A comprehensive review on doxorubicin:
Mechanisms, toxicity, clinical trials, combination therapies and
nanoformulations in breast cancer. Drug Deliv Transl Res.
15:102–133. 2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lovitt CJ, Shelper TB and Avery VM:
Doxorubicin resistance in breast cancer cells is mediated by
extracellular matrix proteins. BMC Cancer. 18(41)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ponce-Cusi R and Calaf GM: Apoptotic
activity of 5-fluorouracil in breast cancer cells transformed by
low doses of ionizing α-particle radiation. Int J Oncol.
48:774–782. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hassanein MM, Hagyousif YA, Zenati RA,
Al-Hroub HM, Khan FM, Abuhelwa AY, Alzoubi KH, Soares NC,
El-Huneidi W, Abu-Gharbieh E, et al: Metabolomics insights into
doxorubicin and 5-fluorouracil combination therapy in
triple-negative breast cancer: A xenograft mouse model study. Front
Mol Biosci. 11(1517289)2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chavez KJ, Garimella SV and Lipkowitz S:
Triple negative breast cancer cell lines: One tool in the search
for better treatment of triple negative breast cancer. Breast Dis.
32:35–48. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Alhammer AH, Alkufi SG, Al-Juboori SI and
Mudhafar SA: KIF15 inhibitor suppresses the proliferation and
migration, and induces the apoptosis of breast cancer cells. World
Acad Sci J. 7(3)2025.
|
|
14
|
Fathi SM, Alhammer AH and Ali IA: Testing
the cytotoxic potential of biosynthesized nanoparticles using
Conocarpus erectus Leaves against human breast cancer cells. AIP
Conf Proc. 2922(040008)2024.
|
|
15
|
Ali SM, Al-Karam LQ and Alhammer AJN: In
vitro cancer cells therapy with nano-gold depending on its optical
properties. NeuroQuantology. 20:57–61. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ahmed ME, Jameel SK and Alhammer AH:
Antibacterial effect and MexA efflux pump Inhibition by
green-synthesized copper nanoparticles from Mentha piperita.
Mol Biol Rep. 52(913)2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Alhammer AH, Al-Juboori SI and Mudhafar
SA: APR-246 enhances the anticancer effect of doxorubicin against
p53-mutant AsPC-1 pancreatic cancer cells. Baghdad Sci J.
21:2551–2560. 2024.
|
|
18
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Alhammer AH, Mudhafar SA and Abdulfattah
SY: Exploring Prima-1(MET) as a single agent or in combination with
tamoxifen in breast cancer cells in vitro. Eur J Pharmacol.
1006(178195)2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kasibhatla S, Amarante-Mendes GP, Finucane
D, Brunner T, Bossy-Wetzel E and Green DR: Acridine Orange/Ethidium
bromide (AO/EB) staining to detect apoptosis. CSH Protoc.
2006(pdb.prot4493)2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Catalano A, Iacopetta D, Ceramella J,
Mariconda A, Rosano C, Scumaci D, Saturnino C, Longo P and
Sinicropi MS: New achievements for the treatment of triple-negative
breast cancer. Appl Sci. 12(5554)2022.
|
|
22
|
Bilgin S: Apoptotic effect of
5-fluorouracil-doxorubicin combination on colorectal cancer cell
monolayers and spheroids. Mol Biol Rep. 51(603)2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dhahi RM: In vitro design of preclinical
models for chemotherapy combinations in human breast tumours. J
Clin Diagn Res. 13:FC05–FC08. 2019.
|
|
24
|
Erden Tayhan S: A study with cancer stem
cells and three-dimensional tumoroids: Investigation of the
combined effects of 5-fluorouracil and doxorubicin in breast
cancer. Med Oncol. 41(185)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zheng M, Mei Z, Junaid M, Tania M, Fu J,
Chen HC and Khan MA: Synergistic role of thymoquinone on anticancer
activity of 5-Fluorouracil in triple negative breast cancer cells.
Anticancer Agents Med Chem. 22:1111–1118. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zoli W, Ulivi P, Tesei A, Fabbri F,
Rosetti M, Maltoni R, Giunchi DC, Ricotti L, Brigliadori G, Vannini
I and Amadori D: Addition of 5-fluorouracil to
doxorubicin-paclitaxel sequence increases caspase-dependent
apoptosis in breast cancer cell lines. Breast Cancer Res.
7:R681–R689. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Surma M, Handy C, Chang J, Kapur R, Wei L
and Shi J: ROCK1 deficiency enhances protective effects of
antioxidants against apoptosis and cell detachment. PLoS One.
9(e90758)2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Dalmases A, González I, Menendez S, Arpí
O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R,
Espinosa L, et al: Deficiency in p53 is required for doxorubicin
induced transcriptional activation of NF-кB target genes in human
breast cancer. Oncotarget. 5:196–210. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu
BY, Yin HR and Lin YZ: Correlation of thymidylate synthase,
thymidine phosphorylase and dihydropyrimidine dehydrogenase with
sensitivity of gastrointestinal cancer cells to 5-fluorouracil and
5-fluoro-2'-deoxyuridine. World J Gastroenterol. 10:172–176.
2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Casale F, Canaparo R, Serpe L, Muntoni E,
Pepa CD, Costa M, Mairone L, Zara GP, Fornari G and Eandi M: Plasma
concentrations of 5-fluorouracil and its metabolites in colon
cancer patients. Pharmacol Res. 50:173–179. 2004.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Barpe DR, Rosa DD and Froehlich PE:
Pharmacokinetic evaluation of doxorubicin plasma levels in normal
and overweight patients with breast cancer and simulation of dose
adjustment by different indexes of body mass. Eur J Pharm Sci.
41:458–463. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sarkar E, Khan A, Ahmad R, Misra A, Raza
ST and Mahdi AA: Synergistic anticancer efficacy of curcumin and
doxorubicin combination treatment inducing S-phase cell cycle
arrest in Triple-Negative breast cancer cells: An in vitro study.
Cureus. 16(e75047)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Camacho KM, Menegatti S, Vogus DR,
Pusuluri A, Fuchs Z, Jarvis M, Zakrewsky M, Evans MA, Chen R and
Mitragotri S: DAFODIL: A novel liposome-encapsulated synergistic
combination of doxorubicin and 5FU for low dose chemotherapy. J
Control Release. 229:154–162. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Minchinton AI and Tannock IF: Drug
penetration in solid tumours. Nat Rev Cancer. 6:583–592.
2006.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Saggar JK, Yu M, Tan Q and Tannock IF: The
tumor microenvironment and strategies to improve drug distribution.
Front Oncol. 3(154)2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Martin M, Villar A, Sole-Calvo A, Gonzalez
R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, et
al: Doxorubicin in combination with fluorouracil and
cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate
in combination with fluorouracil and cyclophosphamide (i.v. CMF
regimen, day 1, 21) as adjuvant chemotherapy for operable breast
cancer: A study by the GEICAM group. Ann Oncol. 14:833–842.
2003.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Saphner T, Tormey DC and Carey P:
Continuous-infusion 5-fluorouracil combined with doxorubicin and
cyclophosphamide: Feasibility study. Med Pediatr Oncol. 20:321–324.
1992.PubMed/NCBI View Article : Google Scholar
|
